Project description:SARS-CoV-2 spike (S) specific T-cell and antibody (AB) responses after primary BNT162b2 vaccination (Pfizer Inc., New York, NY, USA and BioNTech SE, Mainz, Germany) partially depend on the phenotypic composition of pre-existing T-helper (Th) cell populations (Saggau et al., 2022, Immunity). However, adaptive cellular responses and their impact on sustained immune protection after booster vaccination are incompletely understood. We therefore monitored cellular and humoral immune responses before and up to 6 months after the 3rd BNT162b2 vaccination to identify early determinants of sustained responses. As part of an ongoing registry study (Corona Registry Study number 20–426, approved by the ethics committee of the Ludwig Maximilians University Munich), volunteers were recruited among employees of the University Hospital of Augsburg. All subjects had received primary vaccination with two doses of BNT162b2 and were enrolled before their third dose of BNT162b2 (first booster). Exclusion criteria were active infections, receipt of immunomodulatory therapy, pregnancy, positive nucleocapsid-specific (N) IgG titers, and underlying conditions associated with significant impairment of anti-COVID-19 immunity (e.g., diabetes mellitus, cancer, prior stem cell transplantation, or autoimmune diseases). Lithium heparin-anticoagulated whole blood and serum samples were collected immediately before the third vaccination (T0), as well as 1 (T1), 3 (T3), and 6 months (T6) after booster vaccination. No additional booster doses were given during the study period. Serum samples were tested for nucleocapsid (N), S (COBAS e801 immunoassay analyzer with Elecsys Anti-SARS-CoV-2 and Anti-SARS-CoV-2 S (Hitachi Ltd., Tokyo, Japan and Roche Diagnostics GmbH, Basel, Switzerland), and neutralizing AB responses (Haselmann et al., 2020, Clin Chem Med Lab). Subjects developing N IgG or those with incomplete follow-up were excluded. Whole blood was stimulated with co-stimulatory factors anti-CD28 and anti-49d (1 µg/mL Miltenyi Biotec, Bergisch Gladbach, Germany) only, representing the unstimulated/background sample, or additionally S peptides (0.6 nMol/peptide/mL Prot_S, Miltenyi Biotec, Bergisch Gladbach, Germany), as described previously (Lauruschkat et al., 2021, J Fungi (Basel), Weis et al., 2020, Med Mycol). Samples were subsequently analyzed by flow cytometry (data not relevant for this file/analysis) and 13-plex multiplex cytokine assay (LegendPlex Essential Immune Response Panel, BioLegend, San Diego, USA). Significant associations between readouts were identified by multiple testing-adjusted rank correlation analysis. We found moderate correlation between S IgG (r=0.47), S-induced IL-2 (r=0.58) and IFN-γ (r=0.43) at T1 and T6. S IgG, S-induced IL-2, and S-induced IFN-γ at T6 were significantly associated with increased IL 2 & IL 4, IP 10 & MCP1, and IFN-γ & IP 10 levels at T1, respectively (data presented at the 7th Joint Microbiology & Infection Conference of the German Society for Hygiene and Microbiology (DGHM) and the Association for General and Applied Microbiology (VAAM), Wuerzburg, Germany). Subsequently, the preserved T1 RNA samples of the top and bottom half responders at T6 (based on S IgG, S-induced IL-2, and IFN-γ measurements) were isolated via RNeasy Plus Mini Kit (Qiagen, Hilden, Germany) and analyzed by nCounter Immune Exhaustion Panel (Nanostring, Seattle, USA) as described below. At the time of GEO submission of this data (August 2024), the associated manuscript is under review by Frontiers in Immunology.
2024-08-06 | GSE273994 | GEO
